Celldex Therapeutics, Inc. or Novavax, Inc.: Who Leads in Yearly Revenue?

Biotech Giants: Celldex vs. Novavax Revenue Battle

__timestamp	Celldex Therapeutics, Inc.	Novavax, Inc.
Wednesday, January 1, 2014	3586000	30659000
Thursday, January 1, 2015	5480000	36250000
Friday, January 1, 2016	6786000	15353000
Sunday, January 1, 2017	12743000	31176000
Monday, January 1, 2018	9538000	34288000
Tuesday, January 1, 2019	3573000	18662000
Wednesday, January 1, 2020	7418000	475598000
Friday, January 1, 2021	4651000	1146290000
Saturday, January 1, 2022	2357000	1598951000
Sunday, January 1, 2023	6883000	556382000

Cracking the code

Celldex vs. Novavax: A Revenue Race Over the Years

In the competitive landscape of biotechnology, Celldex Therapeutics and Novavax have been pivotal players. From 2014 to 2023, these companies have shown contrasting revenue trajectories. Celldex's revenue peaked in 2017, reaching nearly double its 2014 figures, but has since seen fluctuations. In contrast, Novavax experienced a dramatic surge, especially in 2020, with revenues skyrocketing by over 1500% compared to 2019, largely due to its COVID-19 vaccine efforts. By 2022, Novavax's revenue was approximately 680% higher than Celldex's, highlighting its dominant market position. This data underscores the dynamic nature of the biotech industry, where innovation and timely market responses can lead to significant financial gains. As we look to the future, the question remains: will Celldex find its breakthrough, or will Novavax continue to lead the charge?

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025